Additive manufacturing (AM), which is more popularly referred to as 3D manufacturing is gaining traction in the healthcare industry. The accessibility and flexibility offered by the technology to efficiently produce mechanical systems and monolithic parts has triggered its adoption across the sector. Difficulties associated with consumption of oral drugs is persistent across different age groups. It has been reported that about 50% of individuals face difficulty in consuming oral medications. The difficulties are mainly pertaining to the large size of the capsule and the unpleasant taste amongst other factors. 3D printing of drugs to develop personalized medicines is thus emerging as a substantial and a viable alternative in the field of medical science. The increased reliance of healthcare professionals towards the technology to develop personalized medicine is anticipated to proliferate the growth of the global 3D printed drugs market over the period of next eight years.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=143
The Covid-19 pandemic has amplified the significance of medical supply chain to provide for life-saving drugs. There is an urgent need for manufacturing and distributing medications to the farthest geographical areas. Drug shortages have remained a pressing challenge for countries across the globe. The situation has been worsened and is anticipated to further aggravate due to the pandemic. The increase in demand for oral medications from healthcare facilities along with supply chain concerns has elevated the need for 3D printed drugs. The adoption of AM technologies to enable production of essential drugs within hot spot areas, wherein conventional drugs are unable to reach, are being considered as a viable alternative by the medical fraternity. Substantial initiatives with regards to the same are being undertaken by researchers, companies and hospitals, which indicate substantial growth prospects for the global 3D printed drugs market over the forecast period.
The global 3D printed drugs market is expected to grow at a CAGR of more than 6.2% during the forecast years (2021-2029).
Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=143
The detailed research study provides qualitative and quantitative analysis of 3D printed drugs market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Key Findings of the Report:
- The concerns pertaining to shortage of oral medication is anticipated to fuel the growth of the global 3D printed drugs market over the future years. Infectious disease, oncology, and critical care are among the medical specialties in the United States, which have witnessed major challenges owing to drug shortages.
- 2015 marked the approval of the first 3D printed drug, SPRITAM manufactured by Aprecia Pharmaceuticals. The drug was approved by the U.S. Food and Drug Administration (FDA) to be prescribed as an adjunctive therapy for the treatment of partial onset seizures, primary generalised tonic-clonic seizures and myoclonic seizures across patients with epilepsy.
- The prominent applications of 3D printed drugs, encompassing personalized tablets, controlled released tablets and drug testing are contributing towards the growth of global 3D printed drugs market.
- The 3D printing technologies including fused deposition modeling (FDM), stereolithography (SLA) and selective laser sintering (SLS) are being significantly used for producing 3D printed drugs. Advancements in these technologies to enhance the scope of applications of 3D printed drugs is anticipated to influence the growth of the global 3D printed drugs market over the forecast period.
- Prominent drug manufacturers, such as GlaxoSmithKline Plc., are intensively investing towards 3D printed drugs technology for developing patient-specific dosage forms.
- North America accounted for the highest share in the global 3D printed drugs market. Increased investment into research and development activities from the United States has contributed towards the region’s growth in the global market.
- Some of the major players operating in the global 3D printed drugs market are GlaxoSmithKline Plc., 3D Printer Drug Machine, Aprecia Pharmaceuticals, Hewlett Packard Caribe, BV, LLC, and FabRx Ltd. amongst others.
Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=143
Global 3D Printed Drugs Market:
- By Drug
- Spritam
- Others
- By Region:
- North America
-
- U.S.
- Canada
- Mexico
- Rest of North America
-
- Europe
-
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
-
- Asia Pacific
-
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
-
- Middle East & Africa
-
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Argentina
- Rest of Latin America
-
Get Full Information of this premium report@ https://www.absolutemarketsinsights.com/reports/3D-Printed-Drugs-Market-2018-2026-143
About Us:
Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …
Contact Us:
Email id: [email protected]
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424